Resonance Specialities Ltd

As of December 4, 2025, Resonance Specialty Chemicals is considered overvalued with a PE ratio of 15.31 and an EV to EBITDA of 10.26, despite recent stock performance outpacing the Sensex, indicating its current market price does not reflect an attractive investment opportunity compared to peers like Solar Industries and Godrej Industries.

As of 26-Nov, Resonance Specialities Ltd’s stock price has risen by 0.98% to ₹98.10, continuing a three-day gaining streak that has delivered a 5.3% return over this short period. This upward movement occurs despite the company’s longer-term underperformance relative to key benchmarks, reflecting a complex interplay of recent positive financial results and cautious investor participation.

As of November 19, 2025, Resonance Speci. is fairly valued with a PE ratio of 14.61 and strong growth potential, especially compared to its peers, despite recent underperformance against the Sensex.

As of November 18, 2025, Resonance Speci. is considered an attractive investment due to its undervalued status, with favorable valuation metrics like a PE ratio of 14.26, compared to higher ratios of peers, despite a year-to-date return of -4.79% versus the Sensex's 8.36%.

As of November 17, 2025, Resonance Speciality is fairly valued with a PE ratio of 14.59 and a strong long-term return of 383.89%, despite a recent downgrade from attractive to fair and underperforming the Sensex year-to-date.

As of 06-Nov, Resonance Specialities Ltd's stock price is Rs 90.86, down 4.26%, and has underperformed significantly with a 7.15% decline over the last three days. The stock is trading below key moving averages, indicating a bearish trend, and has seen a notable decrease in delivery volume, reflecting reduced investor interest.

As of November 4, 2025, Resonance Speci. is considered an attractive investment due to its undervalued status, with a PE ratio of 14.64 and favorable comparisons to peers like Godrej Industries and Solar Industries, despite a year-to-date return of -2.27% compared to the Sensex's 6.81%.

As of November 4, 2025, Resonance Speci. is considered undervalued with attractive valuation metrics, including a PE ratio of 14.64 and a PEG ratio of 0.23, despite underperforming the Sensex with a year-to-date return of -2.27%, indicating potential for recovery from its current price of 94.90, significantly lower than its 52-week high of 124.50.

Resonance Speci. has shown fluctuating financial performance, with net sales increasing to 77.81 Cr in Mar'25 from 55.30 Cr in Mar'24, while profit after tax rose to 6.57 Cr. However, the company faced cash flow challenges, reporting a net cash outflow of 1.00 Cr in Mar'25 despite overall growth.

As of November 3, 2025, Resonance Specialty Chemicals is fairly valued with a PE ratio of 15.09, indicating strong growth potential compared to peers, despite recent underperformance against the Sensex.

Resonance Speci. has demonstrated strong growth in net sales and profits, with net sales reaching 77.81 Cr in March 2025, up from 55.30 Cr in March 2024. However, cash flow management remains a challenge, as evidenced by a negative cash outflow of 2.00 Cr in March 2025.

Resonance Specialities' latest results show strong year-on-year growth with a net profit increase of 176.27% and revenue growth of 22.95%, but there are significant sequential declines in both profit and revenue, raising concerns about operational challenges. Overall, the results are mixed, indicating potential sustainability issues despite positive annual metrics.

Resonance Speci. has shown fluctuating financial performance, with net sales increasing to 77.81 Cr in Mar'25 from 55.30 Cr in Mar'24, and profit after tax rising to 6.57 Cr, despite a negative cash flow of 2.00 Cr in Mar'25. Overall, there are improvements in sales and profits but challenges in cash flow management.

As of October 15, 2025, Resonance Speci. is considered undervalued with a favorable valuation grade, highlighted by a PE ratio of 14.35 and strong growth potential, especially when compared to peers like Solar Industries and Gujarat Fluoroch, despite its recent stock performance lagging behind the Sensex.

Resonance Speci. has shown fluctuating historical performance, with net sales increasing to 77.81 Cr in March 2025 but facing challenges in cash flow, which turned negative at -2.00 Cr. Despite growth in profits, total liabilities also rose, indicating financial pressures.